Clinical Trial Update: E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125 [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for E7080 (lenvatinib) in combination with carboplatin and gemcitabine versus carboplatin and gemcitabine alone as second-line therapy in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• E7080 (lenvatinib)

Snippet

Sponsor: Eisai Inc. | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-12-05